Sažetak sa skupa
TRENDS IN THE RATES OF CONSUMPTION OF DRUGS FOR CARDIOVASCULAR SYSTEM AND ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS FROM 2004 – 2017 IN THE REPUBLIC OF CROATIA
Iva Hižar
orcid.org/0000-0002-8300-4095
; Sveučilište u Zagrebu, Medicinski fakultet, Zagreb, Hrvatska
Sandro Gašpar
orcid.org/0000-0001-8941-1831
; Sveučilište u Zagrebu, Medicinski fakultet, Zagreb, Hrvatska
Marjeta Majer
; Sveučilište u Zagrebu, Medicinski fakultet, Škola narodnog zdravlja Andrija Štampar, Zagreb, Hrvatska
Sažetak
Introduction: In the Republic of Croatia, cardiovascular diseases and malignant neoplasms are the two leading causes of death. The main purpose of this study was to analyse trends in the rates of consumption of drugs for cardiovascular system (group C) and antineoplastic and immunomodulating agents (group L) over the past 14 years.
Methods: Analysis of drug consumption based on anatomical therapeutic chemical (ATC) classification system for the group of drugs for cardiovascular system and the group of antineoplastic and immunomodulating agents in Croatia for the period 2004 -2017 was presented in Croatian kuna (HRK) and in defined daily doses/1000 inhabitants/day.
For this study, we used data from the reports on drug consumption published at the website of The agency for medicinal products and medical devices of Croatia (HALMED).
Results: According to the available data on drug consumption in Croatia from 2004 – 2017, there was increase in total drug consumption from 3.824.758.092,00 HRK in 2004 up to 6.131.627.475,00 HRK in 2017 and increase of drug usage from 658,14 DDD/1000/day in 2004 up to 1.061,11 DDD/1000/day in 2017. Analyzing the total drug consumption by financial indicators for each of the individual ATC group, there is an evident increase in the costs of all drug groups, except in the costs of drugs for cardiovascular system (group C), whose costs were 856.458.507,00 HRK in 2004, and 785.013.401,00 HRK in 2017.
At the same time, the consumption for the same group of drugs by DDD/1000/day increased from 251.95 DDD/1000/day in 2004 up to 386.38 DDD/1000/day in 2017. The relative share of costs for Group C fell from ¼ of total drug costs (22% in 2004, 26% in 2005, 26% in 2006) to 13% in 2017. The greatest increase in total drug consumption according to financial indicators occurred in the group of antineoplastic and immunomodulating agents (group L), whose costs were 185.263.054,00 HRK in 2004 and 1.321.313.353,00 HRK in 2017.
The increase in total drug costs for the Group L is followed by an increase in drug consumption presented in DDD/1000/day from 2.30 DDD/1000/day in 2004 to 8.38 DDD/1000/day in 2017.
The relative share of costs for Group L has increased from 5% of total drug costs in 2004 to as much as 22% in 2017, what makes the greatest increase in relative costs of all drug groups.
Among the top ten drugs with highest total financial consumption in hospitals in 2017, even eight drugs belong to group L of drugs, furthermore, they also take the first four places (trastuzumab, rituximab, adalimumab, and bevacizumab).
Conclusion: Analysis of the available data on drug consumption based on anatomical therapeutic chemical classification system in the Republic of Croatia over the past 14 years, revealed the reduction in the costs of the group C, despite an increase in defined daily doses per 1000 inhabitans for 134.43 DDD/1000/day, what may be caused by drops in prices of the group C. At the same time, there was a significant increase in the costs of the group L drugs, as well as in defined daily doses for the same group.
Ključne riječi
cardiovascular drugs; antineoplastic drugs; health expenditures
Hrčak ID:
218583
URI
Datum izdavanja:
31.12.2018.
Posjeta: 1.113 *